✦ LIBER ✦

Differential effect of Huntington's and Parkinson's diseases in programming motor sequences of varied lengths

✍ Scribed by L. Yágüez; H. W. Lange; V. Hömberg

Book ID: 106093107
Publisher: Springer
Year: 2005
Tongue: English
Weight: 338 KB
Volume: 253
Category: Article
ISSN: 0340-5354
DOI: 10.1007/s00415-005-0951-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Motor learning by imagery is differentia

Motor learning by imagery is differentially affected in Parkinson’s and Huntington’s diseases

✍ Lidia Yágüez; Anthony G.M Canavan; Herwig W Lange; Völker Hömberg 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Unawareness of dyskinesias in Parkinson'

Unawareness of dyskinesias in Parkinson's and Huntington's diseases

✍ C. Vitale; M. T. Pellecchia; D. Grossi; N. Fragassi; T. Cuomo; L. Di Maio; P. Ba 📂 Article 📅 2001 🏛 Springer Milan 🌐 English ⚖ 44 KB

Effects of Coenzyme Q10 in Huntington's

Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease

✍ M. Flint Beal; Clifford W. Shults 📂 Article 📅 2003 🏛 IOS Press 🌐 English ⚖ 62 KB

Deleterious effects of minocycline in an

Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease

✍ Elsa Diguet; Pierre-Olivier Fernagut; Xing Wei; Yansheng Du; Richard Rouland; Ch 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB

Neuropsychological and Behavioral Aspect

Neuropsychological and Behavioral Aspects of Transplants in Parkinson's Disease and Huntington's Disease

✍ Nico J. Diederich; Christopher G. Goetz 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Differential progression of motor impair

Differential progression of motor impairment in levodopa-treated Parkinson's disease

✍ Christopher G. Goetz; Glenn T. Stebbins; Lucy M. Blasucci 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 2 views

OBJECTIVE: To monitor comparative progression of clinical impairment over 4 years in patients with Parkinson's disease (PD) who present on levodopa at two different levels of Hoehn and Yahr (HY) stages, II and III. BACKGROUND: The rate of clinical impairment progression in patients with PD being tr